Malnutrition and Sarcopenia Among Primary Ciliary Dyskinesia (Malnutrition)
Associations Between the Status of Malnutrition and Sarcopenia in Children and Adolescents With Primary Ciliary Dyskinesia
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Kerim Kaan K GÖKÜSTÜN, Dr. Lecturer
- Número de teléfono: +90 232 299 07 39
- Correo electrónico: kerimkaangokustun@hotmail.com
Copia de seguridad de contactos de estudio
- Nombre: Gülşah BARĞI, Assoc. Dr.
- Número de teléfono: +90 232 299 07 39
- Correo electrónico: gulsahbargi35@gmail.com
Ubicaciones de estudio
-
-
-
Izmir, Turquía (Türkiye), 35140
- Izmir Democracy University
-
Contacto:
- Kerim K GÖKÜSTÜN, Dr. Lecturer
- Número de teléfono: 05058699032
- Correo electrónico: kerimkaangokustun@hotmail.com
-
Contacto:
- Gülşah BARĞI, Assoc. Dr.
- Correo electrónico: gulsahbargi35@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
Inclusion criteria for children and adolescents with PCD
- Unexplained neonatal respiratory distress, lateralization defect, productive cough, bronchiectasis, daily nasal congestion, and pansinusitis, as well as laboratory tests such as high-speed video microscopy, transmission electron microscopy, or genetic testing according to the European Respiratory Society diagnostic guidelines.
- Cooperative individuals,
- Individuals who have never smoked
- Willingness to participate in the study
Inclusion criteria for healthy children and adolescents:
1. Voluntary participation in the study
Exclusion Criteria:
Exclusion criteria for children and adolescents with PCD:
- Individuals with any acute, chronic, or systemic illness other than PCD
- Individuals who smoke or are quitting smoking
- Individuals who are not willing to participate in the study
- Individuals who are uncooperative
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Patient of Primary Ciliary Dyskinesia
The study will include children and adolescents with PCD aged 6 to 18 (n=15).
|
Participants will be evaluated in terms of nutritional status, anthropometric measurements (waist circumference, hip circumference, waist-to-height ratio, skinfold measurements) and body composition, pulmonary functions, anaerobic capacity, muscle strength.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Handgrip Muscle Strength in Participants
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Bilateral grip strength in children and adolescents with PCD will be measured in kgF using a hand dynamometer.
|
From enrollment to the end of treatment at 1 year
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Malnutrition risk score in Participants
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
The Nutritional Status and Growth Risk Screening Tool will be used to assess the risk of growth failure.
The total score on this scale ranges from 0 to 5; a score of 0 indicates a low risk of malnutrition, a score of 1-3 indicates a moderate risk of malnutrition, and a score of 4-5 indicates a high risk of malnutrition.
|
From enrollment to the end of treatment at 1 year
|
|
Body Weight
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Body weight in children and adolescents with PCD will be measured using a pediatric scale.
|
From enrollment to the end of treatment at 1 year
|
|
Height
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, height will be measured using a stadiometer.
|
From enrollment to the end of treatment at 1 year
|
|
Body Mass Index
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
For children and adolescents with PCD, the body mass index will be calculated by dividing body weight by the square of height in meters.
|
From enrollment to the end of treatment at 1 year
|
|
Waist circumference
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Waist circumference in children and adolescents with PCD will be measured using a tape measure
|
From enrollment to the end of treatment at 1 year
|
|
Hip circumference
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Hip circumference in children and adolescents with PCD will be measured using a tape measure
|
From enrollment to the end of treatment at 1 year
|
|
Waist-to-hip ratio
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, the waist-to-hip ratio will be calculated by dividing the waist circumference by the hip circumference.
|
From enrollment to the end of treatment at 1 year
|
|
Waist-to-Height ratio
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, the waist-to-height ratio will be calculated by dividing the waist circumference by the height.
|
From enrollment to the end of treatment at 1 year
|
|
Upper-middle arm circumference
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, upper arm circumference will be measured using a non-stretchable tape measure, without tightening it or leaving any slack.
|
From enrollment to the end of treatment at 1 year
|
|
Triceps skinfold thickness
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
In children and adolescents with PCD, triceps skinfold thickness will be measured using a skinfold caliper.
|
From enrollment to the end of treatment at 1 year
|
|
Body fat percentage
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Body fat percentage in children and adolescents with PCD will be measured using bioelectrical impedance analysis.
|
From enrollment to the end of treatment at 1 year
|
|
Height by Age
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
The percentile values for height by age in children and adolescents with PCD will be determined using data from the CDC's website.
|
From enrollment to the end of treatment at 1 year
|
|
Weight by Height
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
The percentile values for Weight by Height in children and adolescents with PCD will be determined using data from the CDC's website.
|
From enrollment to the end of treatment at 1 year
|
|
Weight by Age
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
The percentile values for Weight by Age in children and adolescents with PCD will be determined using data from the CDC's website.
|
From enrollment to the end of treatment at 1 year
|
|
Body Mass Index by Age
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Body Mass Index (BMI) is an anthropometric index calculated by dividing body weight in kilograms by the square of height in meters.
Body Mass Index by Age (BMI-for-Age) is the body mass index (BMI) adjusted for age and sex and interpreted using age- and sex-specific growth reference charts.The percentile values for Body Mass Index by Age in children and adolescents with PCD will be determined using data from the CDC's website.
|
From enrollment to the end of treatment at 1 year
|
|
Forced Expiratory Volume at One Second
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Forced Expiratory Volume at One Second is the volume of air that an individual can forcibly exhale during the first second of a maximal forced expiration following a full inspiration.
It is typically expressed in liters or as a percentage of the predicted value (% predicted).
|
From enrollment to the end of treatment at 1 year
|
|
Forced Vital Capacity
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Forced Vital Capacity is the total volume of air that an individual can forcibly exhale after taking a maximal inspiration.
It is typically expressed in liters (L) or as a percentage of the predicted value (% predicted).
|
From enrollment to the end of treatment at 1 year
|
|
Forced Expiratory Volume at One Secondto Forced Vital Capacity Ratio
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Forced Expiratory Volume at One Second to Forced Vital Capacity Ratio is the proportion of the forced vital capacity that is exhaled during the first second of a forced expiration following a maximal inspiration.
It is expressed as a percentage.
|
From enrollment to the end of treatment at 1 year
|
|
Peak Expiratory Flow
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Peak Expiratory Flow is the maximum expiratory flow rate achieved during a forced expiration following a maximal inspiration.
It is typically expressed in liters per minute.
|
From enrollment to the end of treatment at 1 year
|
|
Forced Expiratory Flow at 25-75% of Forced Vital Capacity
Periodo de tiempo: From enrollment to the end of treatment at 1 year
|
Forced Expiratory Flow at 25-75% of Forced Vital Capacity is the average forced expiratory flow measured during the middle 50% of the forced vital capacity maneuver, specifically between 25% and 75% of the exhaled volume.
It is typically expressed in liters per second.
|
From enrollment to the end of treatment at 1 year
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Gülşah BARĞI, Assoc. Dr., Izmir Democracy University
- Director de estudio: Kerim K Göküstün, Dr. Lecturer, Izmir Democracy University
- Investigador principal: Aybüke Sena DEMİR, MSc., Izmir Democracy University
- Investigador principal: Ece OCAK, Dr., University of Health science
Publicaciones y enlaces útiles
Publicaciones Generales
- Despotes KA, Zariwala MA, Davis SD, Ferkol TW. Primary Ciliary Dyskinesia: A Clinical Review. Cells. 2024 Jun 4;13(11):974. doi: 10.3390/cells13110974.
- McCoy J, Gatt D, Shaw M, Solomon M, Kritzinger F, Ratjen F. The Impact of Nutritional Status on Lung Function Trajectories in Pediatric Patients With Primary Ciliary Dyskinesia. Pediatr Pulmonol. 2026 Apr;61(4):e71634. doi: 10.1002/ppul.71634.
- Karavasiloglou N, Gkatzou V, Fernandez-Rodriguez A, Schwartz V, Goutaki M. Nutrition and growth of primary ciliary dyskinesia patients: a systematic review. Eur Respir Rev. 2026 May 27;35(180):260024. doi: 10.1183/16000617.0024-2026. Print 2026 Apr.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Ciliopatías
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Manifestaciones Neuromusculares
- Trastornos Nutricionales
- Condiciones Patológicas, Anatómicas
- Enfermedades Genéticas Congénitas
- Enfermedades de las vías respiratorias
- Anomalías congénitas
- Enfermedades Otorrinolaringológicas
- Anomalías Múltiples
- Atrofia Muscular
- Atrofia
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Signos y síntomas
- Desnutrición
- Trastornos de la motilidad ciliar
- Sarcopenia
Otros números de identificación del estudio
Otros números de identificación del estudio
- Primary Ciliary Dyskinesia
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .